Oncotarget

Reviews:

Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy

Hongyu Liu, Ling Chen, Yaojun Peng, Songyan Yu, Jialin Liu, Liangliang Wu, Lijun Zhang, Qiyan Wu, Xin Chang, Xinguang Yu and Tianyi Liu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:2887-2894. https://doi.org/10.18632/oncotarget.20812

Metrics: PDF 1198 views  |   HTML 1970 views  |   ?  


Abstract

Hongyu Liu1,*, Ling Chen1,*, Yaojun Peng2, Songyan Yu3, Jialin Liu1, Liangliang Wu2, Lijun Zhang2, Qiyan Wu2, Xin Chang4, Xinguang Yu1 and Tianyi Liu2

1Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China

2Key Laboratory of Cancer Center, Chinese PLA General Hospital, Beijing 100853, China

3Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China

4Department of Clinical Laboratory, Weihai Municipal Hospital, Weihai 264200, Shandong, China

*Co-first author

Correspondence to:

Tianyi Liu, email: tianyiliu08@hotmail.com

Xinguang Yu, email: xinguang_yu@263.net

Keywords: tumor derived exosomes, dendritic cells, immunotherapy

Received: October 21, 2016     Accepted: April 29, 2017     Published: September 11, 2017

ABSTRACT

Exosomes are vesicles that can be secreted by many types of cell and released into the extracellular space. Studies have found that tumor derived exosomes (TEXs) can promote tumor growth and metastasis, as well as inhibit immune response through transferring their genetic information to the recipient cells. Given their functions in tumor progression, TEXs are considered as promising biomarkers for early detection of human malignancy. Dendritic cells (DCs), a type of antigen presenting cells, can induce tumor-specific T cell immune responses in carcinogenesis. Growing evidences have demonstrated that the matured DCs induced by TEXs exhibit enhanced anti-tumor effects that may be applied for cancer immunotherapy. Thus in this review, according to the previous studies, we summarized the effects of DCs loaded with TEXs in cancer immunotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20812